Upgrade to ChromeUpgrade to FirefoxUpgrade to Internet ExplorerUpgrade to Safari

About Us

Speak to our team

Contact us today to see how we can help

Contact Us

We are an independent consultancy specialising in health economic modelling, outcomes research and statistical analysis. Established in 2011, we cover the breadth of market access, pricing and reimbursement activities. Our particular area of expertise is disease modelling and the multivariate analysis of large healthcare databases to support health technology assessment (HTA) and undertake scientific research.

Why HEOR Ltd?

What sets us apart from other agencies is a combination of research and academic excellence, strategic awareness, and a dedication to providing innovative and novel solutions to research projects and deliverables.

Our experience and unique perspectives set us apart in navigating the complex interactions between healthcare payers, the pharmaceutical industry, patients and clinicians.

We pride ourselves on academic rigour, research excellence, and a flexible, client-focused model of business engagement.

Senior Leadership Team

HEOR Ltd is led by Professors Phil McEwan and Jason Gordon, who are supported by a team of experienced and dedicated medical writers, economists, statisticians, computer scientists, mathematicians and operational research analysts, and has access to extensive research expertise through its association with universities, other vendors and key opinion leaders.

View our full team

Training and Education

Economic evaluations of healthcare interventions routinely focus on population level cost-effectiveness analyses to support reimbursement decisions; the so-called ‘Fourth Hurdle’. Yet what is informative at the policy level does not always translate meaningfully to the local population or individual patient level.Population level analyses consider the ‘average patient’, while local payers and prescribers work with a group of individual patients with specific characteristics and health challenges. Translating the findings of policy level analyses to individual patients requires a full understanding of drivers of economic value and consequent affordability. Demonstrating value to payers and prescribers is increasingly recognised as the ‘Fifth Hurdle’.

View Case Study

Contact us today to see how we can help

Contact Us